N-[1-(2-carboxy-4-phenylbutyl)-cyclopentane-carbonyl]-(S)-isoserine | 565453-96-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[1-(2-carboxy-4-phenylbutyl)-cyclopentane-carbonyl]-(S)-isoserine
• 英文别名: 2-[[1-[[(2S)-2-carboxy-2-hydroxyethyl]carbamoyl]cyclopentyl]methyl]-4-phenylbutanoic acid
• CAS: 565453-96-5
• 化学式: C₂₀H₂₇NO₆
• 分子量: 377.437
• InChiKey: OSJSRBCOQRHXEC-LYKKTTPLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：INTRA CELLULAR THERAPIES INC

  公开号：WO2016022893A1

  公开（公告）日：2016-02-11

  The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

  该发明涉及新型磷酸二酯酶1（PDE1）抑制剂，用于治疗由于某些cGMP/PKG介导的途径受到破坏或损害而表现出的疾病或紊乱（例如在心脏组织中）。该发明还涉及包含该抑制剂的药物组合物以及治疗心血管疾病和相关疾病的方法，例如充血性心力衰竭、动脉粥样硬化、心肌梗死和中风。
• ORGANIC COMPOUNDS
  申请人：Intra-Cellular Therapies, Inc.

  公开号：US20160039829A1

  公开（公告）日：2016-02-11

  The invention relates to novel inhibitors of phosphodiesterase 1 (PDE1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cGMP/PKG mediated pathways (e.g., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

  本发明涉及新型磷酸二酯酶1（PDE1）抑制剂，用于治疗由于某些cGMP/PKG介导的通路（例如在心脏组织中）受到破坏或损伤而表现出的疾病或障碍。本发明还涉及包含该抑制剂的制药组合物以及用于治疗心血管疾病和相关疾病的方法，例如充血性心脏病，动脉粥样硬化，心肌梗死和中风。
• COMPOUNDS CONTAINING S-N-VALERYL-N--VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS
  申请人：Feng Lili

  公开号：US20160324821A1

  公开（公告）日：2016-11-10

  A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.

  一种治疗心血管或肾脏疾病的方法，使用特定组合、联接型前药或血管紧张素受体拮抗剂和NEPi化合物。
• Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
  申请人：SCHERING CORPORATION

  公开号：EP0509442A1

  公开（公告）日：1992-10-21

  Treatment and prevention of immunosuppression therapy-induced nephrotoxicity with neutral endopeptidases such as N-[N-[(L)-[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)-methoxy]carbonyl]-2-phenylethyl]-L-phenylalanyl]-β-alanine and N-[2-mercaptomethyl-3-(2-methylphenyl)propioyl]-methionine are disclosed.

  本研究公开了用中性内肽酶（如 N-[N-[(L)-[1-[(2,2-二甲基-1,3-二氧戊环-4-基)-甲氧基]羰基]-2-苯基乙基]-L-苯基丙氨酰]-β-丙氨酸和 N-[2-巯甲基-3-(2-甲基苯基)丙酰]-甲硫氨酸）治疗和预防免疫抑制疗法引起的肾毒性。
• Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation
  申请人：SCHERING CORPORATION

  公开号：EP0533084A1

  公开（公告）日：1993-03-24

  Treatment or prevention of myointimal proliferation in atherosclerosis, restenosis induced by angioplasty or vascular reconstructive surgery, glomerulonephritis, glomerulosclerosis or other diseases involving vascular cell proliferation, with a natriuretic peptide or a neutral endopeptidase inhibitor such as N-[N-[(L)-[1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]carbonyl]-2-phenylethyl]-L-phenylalanyl]-β-alanine and N-[2-mercaptomethyl-3-(2-methylphenyl)propionyl]-methionine, or with a neutral endopeptidase inhibitor in combination with a natriuretic peptide or an angiotensin converting enzyme inhibitor are disclosed.

  使用钠尿肽或中性内肽酶抑制剂，如 N-[N-[(L)-[1-[(2. 2-二甲基-1,3-二氧戊环-4-基)甲氧基]羰基]-2-苯基乙基]-L-苯基丙氨酰]-β-丙氨酸，治疗或预防动脉粥样硬化、血管成形术或血管重建手术引起的再狭窄、肾小球肾炎、肾小球硬化或其他涉及血管细胞增生的疾病中的肌内膜增生、2-甲基-1,3-二氧戊环-4-基)甲氧基]羰基]-2-苯基乙基]-L-苯丙氨酰]-β-丙氨酸和 N-[2-巯甲基-3-(2-甲基苯基)丙酰基]-甲硫氨酸，或中性内肽酶抑制剂与利钠肽或血管紧张素转换酶抑制剂联合使用。